01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia
DOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST
01 March 2024 : Editorial
DOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.